Loading...
Loading...
Deutsche Bank is out with a research report on Fluidigm
FLDM and it has a Buy rating and a $18 price target on shares.
In a note to clients, Deutsche Bank writes, "Key takeaways from CC: 1) In-line revenues, with BioMark / Access Array demand
driven by single cell analysis / next gen sample prep applications; 2) Installed base of instruments at 440, with 60% of sales in the Q driven by analytical instruments (remaining by sample prep); 3) Raised FY11 product revenue growth guidance to a
range of 31%-33% from prior 27%-30%. We believe that the company's innovative technology positions it well for future growth, so reiterate our Buy rating. PT goes to $18.00 (was $21.00 prior) on peer multiple contraction."
Shares of FLDM are off 37 cents to $13.28.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in